Healthy outcome under olanzapine treatment in a pregnant woman.
Our report focuses on the case of a pregnant women with recurrent, paranoid schizophrenia. The patient was treated with Olanzapine from the 18th gestational week until delivery and during breast-feeding. No adverse events occurred during pregnancy, and the outcome was healthy. After delivery, the plasma level of olanzapine in the infant was one-third of the maternal plasma level, and during breast-feeding, it decreased to an undetectable limit.